



Safe Harbour Statement

Before we may start with the presentations, we need to remind you that the information made available in this conference call may include forward-looking statements that reflect the intentions, beliefs or current expectations and projections of COLTENE Holding AG about the future results of operations, financial condition, liquidity, performance and similar circumstances. Such statements are made on the basis of assumptions and expectations which may prove to be erroneous, although COLTENE Holding AG believes them to be reasonable at this time.



Content

- COLTENE New Dental Standalone
- · Strengthened Management
- · Dental Business
- Financials
- Outlook
- Q&A

3




Highlights 1HY2008


- Dental Business at constant June 2007 translation rates
 - Sales up 8.4% vs. previous year
 - EBIT up 1.5% vs. previous year
- · Achieved 1.8 CHFm more in Net Sales in Q2 vs. Q1
- Free cash flow raised by 52% in 1HY2008
- Earnings per share CHF 8.04
- Equity ratio 81%




COLTENE at a glance....today

- April 2008: sale of Medical business (Medisize)
- New Dental stand-alone COLTENE®
- Clear focus on dentistry, an attractive long-term growth market
- Good profitability and continuously excellent free cash flows
- Strong and solid balance sheet
- Good base for organic growth and acquisitions
- · Attractive dividend yield









Growth: Achievements in 1HY2008

- Composite curing-lights business grew by >40% YoY (esp. LED lights)
- Rotary instruments business increased by >30% in 1HY08 vs. 1HY07 (esp. CEI carbide burs)
- Strong growth in condensation silicones (+20%) in emerging markets YoY
- Endo line (i.e. fiber posts) grew by 10% YoY
- Successful launch of new bonding material (7th generation One Coat Bond) in 1HY2008


q





Growth: Achievements (cont.)

- Affinis impression material for implants launched in June 2008 – will leverage A-Silicone business
- Whole range of COLTENE products perfectly matches implantology procedures
 - Affinis impression product family
 - Cool Temp temporary material
 - Jet Blue Bite registration material
 - Para Cem universal cement
 - New implantology brochure showing treatment steps for optimal application





Growth – Geographical Expansion

- · Focus on Emerging Markets
 - China: New COLTENE subsidiary successfully started and looking at doubling turnover in 2008
 - India: documents for new subsidiary submitted to the authorities in 1HY2008
 - Russia: active expansion activities led to high double digit growth YoY
 - Evaluation of local manufacturing as well as filling and packaging still ongoing

13



Growth – Focus Acquisition


- Targets identified (short list)
- · Working actually at the top 3 projects
- · Projects support both
 - product / market emphasis
 - geographical expansion
- Targets need to support direct selling capabilities



Further Highlights 1HY2008

- CEI production increased to 3 shifts: gain of >30% in capacity
- Strong increase of market-specific composite (filling material) in Latin America and Eastern Europe
- Strengthened COLTENE brand by positioning the new dental stand-alone company
- Expanded dealer network in emerging markets to support planned growth







Financials 1HY2008


17

COLTENE®

Growth in Net Sales

1'000 CHF	1 HY 08	%	1 HY 07	%	% YoY
Net Sales	81'915	100.0%	81'068	100.0%	1.0%
Raw materials	22'665	27.7%	22'625	27.9%	0.2%
Personnel expenses	29'336	35.8%	27'866	34.4%	5.3%
Other expenses	18'314	22.4%	16'861	20.8%	8.6%
Depreciation&amortization	2'084	2.5%	2'151	2.7%	-3.1%
Total operating expenses	49'734	60.7%	46'878	57.8%	6.1%
EBIT	9'516	11.6%	11'565	14.3%	-17.7%

Net Sales currencies adjusted **87'888 107.3% 81'068 100.0% 8.4%**



COLTENE® High Profit for the Period 1'000 CHF 1 HY 08 % 1 HY 07 % % YoY **EBIT** 9'516 11.6% 11'565 14.3% -17.7% -0.7% Financial result (net) -0.1% 1019.6% -571 -51 Net profit before tax 8'945 10.9% 11'514 14.2% -22.3% Tax expenses -1'959 -2.4% -2'836 -3.5% -30.9% In % of net profit before tax 21.9% 24.6% Net profit cont. operations 6'986 8.5% 8'678 10.7% -19.5% Profit discont. operations 29'700 36.3% 3'742 4.6% 693.7% 12'420 15.3% Profit for the period 36'686 44.8% 195.4% 20



Excellent Free Cash Flow

1'000 CHF	1 HY 08	%*	1 HY 07	%*	% YoY
CF from operations**	10'899	13.3%	7'125	8.8%	53.0%
Purchase & proceeds PPE**	-1'798		-789		
Purchase fin. & intangibles**	-179		-343		
Purchase of subsidiaries**	0		-9'414		
CF from investments**	-1'977		-10'546		
FCF prior acquisitions**	8'922	10.9%	5'993	7.4%	48.9%

^{*:} in % of net sales; **: continuing operations only

21



Strong Balance Sheet

1'000 CHF	30.06.08	31.12.07	<u> </u>
Cash & cash equivalents	62'725	13'367	7
Receivables	43'941	57'755	5
Inventory	29'600	49'846	6
Property, plant & equipment	28'625	57'596	3
Financial, intangible & tax assets	45'374	69'004	ļ
Total assets	210'265	247'568	3
Payables & short term liabilities	27'441	29'186	6
Bank loans & other loans	7'095	36'555	5
Other long term liabilities	4'928	16'162	<u>)</u>
Equity (equity ratio)	170'801	81.2% 165'665	66.9%
Total liabilities & equity	210'265	247'568	3



High Profit from Sale of Medical

1'000 CHF	1 HY 08
Profit after tax discontinued operations 1-4 2008	1'419
Gain after tax on sale of discontinued operations	28'281
Profit from discontinued operations	29'700
Disposed assets discontinued operations	89'014
Disposed liabilities discontinued operations	20'646
Net disposals discontinued operations	68'368
Net cash flow discontinued operations 1-4 2008	1'077
Net cash flow on sale of discontinued operations	93'426
Net cash flow from discontinued operations	94'503
Consideration received, satisfied in cash	102'817
Costs of disposal, satisfied in cash	-4'299
Cash disposed of	-5'092
Net cash flow on sale of discontinued operations	93'426

23

COLTENE®

COLTENE Outlook 2008 - Update

Assumptions:

• Dental market consumables sales growth ≥ 3.5%

Forex rate: USD / CHF = 1.05
Forex rate: EUR / CHF = 1.60

Indications:

• COLTENE Sales CHFm 170

• COLTENE EBIT CHFm 27.5 (16.2%)

Sales growth rates without forex impact 7.5%





Thank you very much for your attention!

Q & A